Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Beyond efficacy: health inequities limiting access to semaglutide for obesity management
Postgraduate medical journal, 2026
Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication
Obesity (Silver Spring, Md.), 2026
Future GLP-1 receptor co-agonists and their cardiac effects
Naunyn-Schmiedeberg's archives of pharmacology, 2026
AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026
Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants
Journal of visualized experiments : JoVE, 2026;(235)
Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol
Obesity science & practice, 2026;12(5):e70200
Food noise: A theoretical review
Appetite, 2026;:108791
Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment
Health affairs scholar, 2026;4(10):qxag255
Effects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review
Cureus, 2026;18(9):e116733
Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System
Cureus, 2026;18(9):e116758
GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study
Age and ageing;55(9)
Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic
Journal of health care for the poor and underserved;37(1):270-286
Euglycaemic ketoacidosis associated with dual-acting GLP-1/GIP receptor agonist treatment following bariatric surgery
Endocrinology, diabetes & metabolism case reports;2026(3)
Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care 2026;49:XXXX-XXXX
Diabetes care, 2026
Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling
The Journal of clinical endocrinology and metabolism, 2026
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis
Diabetes, obesity & metabolism, 2026
Real-World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERS
Diabetes, obesity & metabolism, 2026
Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes
Diabetes, obesity & metabolism, 2026
Combination pharmacotherapy for MASH: Potential synergistic approaches
Biochemical pharmacology, 2026;:118492
Adjuvant Glucagon-like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis
The Journal of surgical research, 2026;327:158-165